SCHEMBL22855710

SCHEMBL22855710

C#CCOC1C(OC)C(COC)OC1n1cnc2c(N)ncnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHCY P23526 5/20 0.50
▸ ADORA3 P0DMS8 5/20 0.48
▸ GAA P10253 1/20 0.47
▸ ADORA1 P30542 4/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ ADORA2A P29274 2/20 0.47
▸ ADORA2B P29275 2/20 0.47
▸ DPP4 P27487 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ SLC28A1 O00337 1/20 0.47
▸ MAP3K7 O43318 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ GAPDH P04406 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ STAT6 P42226 1/20 0.47
▸ PI4KA P42356 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ PI4K2B Q8TCG2 1/20 0.47
▸ DOT1L Q8TEK3 1/20 0.47
▸ SLC29A1 Q99808 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22855712 0.91 AHCY (0.49) AHCYADORA3GAAADORA1SMN1; SMN2
SCHEMBL21999229 0.90 AHCY (0.56) AHCYADORA3ADORA1SMN1; SMN2ADORA2A
SCHEMBL21999054 0.89 ADORA3 (0.56) AHCYADORA3ADORA1SMN1; SMN2ADORA2A
SCHEMBL12376385 0.89 ADORA3 (0.56) AHCYADORA3ADORA1SMN1; SMN2ADORA2A
SCHEMBL12360836 0.89 ADORA3 (0.56) AHCYADORA3ADORA1SMN1; SMN2ADORA2A
SCHEMBL24891556 0.89 ADORA1 (0.50) ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2
SCHEMBL12646696 0.88 ADORA1 (0.52) ADORA3GAAADORA1SMN1; SMN2ADORA2A
SCHEMBL12015179 0.88 ADORA1 (0.52) ADORA3GAAADORA1SMN1; SMN2ADORA2A
SCHEMBL22855775 0.88 ADORA1 (0.52) ADORA3GAAADORA1SMN1; SMN2ADORA2A
SCHEMBL12590110 0.88 ADORA1 (0.52) ADORA3GAAADORA1SMN1; SMN2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2022-04-28 — — US disclosed
US-20220056451-A1 HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE ALIGOS THERAPEUTICS, INC. 2022-02-24 — — US disclosed
US-11166976-B2 S-antigen transport inhibiting oligonucleotide polymers and methods ALIGOS THERAPEUTICS, INC. (US) 2021-11-09 — — US disclosed
US-20200405743-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056451-A1 HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE HAVCR2, POLRMT, DCLRE1B AHCY 695/4885ADORA3 1448/4885GAA 2145/4885
US-11166976-B2 S-antigen transport inhibiting oligonucleotide polymers and methods RNGTT, PHAX, HAVCR2 AHCY 532/4885ADORA3 1372/4885GAA 52/4885
US-20200405743-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS RNGTT, PHAX, HAVCR2 AHCY 532/4885ADORA3 1372/4885GAA 52/4885
US-20220125825-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS RNGTT, PHAX, HAVCR2 AHCY 532/4885ADORA3 1372/4885GAA 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback